Search research articles
Contact Us
Filters
Showing results (481-490 of 603) with videos related to
Page
of 61
Sort By:
British Journal of Haematology
|
March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study
Loretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Haematologica
|
November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Raphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
Leukemia
|
May 25, 2019
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells
Fen Zhu, Hui Guo, Paul D Bates, et al.
JAMA Oncology
|
July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial
Chelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Oncotarget
|
December 15, 2015
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
Hongyu Li, Jing Hu, Shuhong Wu, et al.
Nature Communications
|
July 2, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance
Soo-Yeon Hwang, Xiangao Huang, Helgi Nikolli, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation
Ryan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Journal of Hematology & Oncology
|
October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Keshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Medicine
|
September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
The Lancet. Oncology
|
February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Michael Wang, Wojciech Jurczak, Marek Trneny, et al.
Page
of 61
Search research articles
Search
Showing results (481-490 of 603) with videos related to
Sort By:
Page
of 61
British Journal of Haematology
|
March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study
Loretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Haematologica
|
November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Raphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
Leukemia
|
May 25, 2019
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells
Fen Zhu, Hui Guo, Paul D Bates, et al.
JAMA Oncology
|
July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial
Chelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Oncotarget
|
December 15, 2015
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
Hongyu Li, Jing Hu, Shuhong Wu, et al.
Nature Communications
|
July 2, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance
Soo-Yeon Hwang, Xiangao Huang, Helgi Nikolli, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation
Ryan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Journal of Hematology & Oncology
|
October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Keshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Medicine
|
September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
The Lancet. Oncology
|
February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Michael Wang, Wojciech Jurczak, Marek Trneny, et al.
Page
of 61